Abstract 436P
Background
With the advent of personalized medicine, recent clinical trials have placed much emphasis on the OS and PFS of cancer patients. However, several international guidelines also emphasize the need for assessing the Health Related Quality of Life (HRQoL) as part of our holistic approach in the management of cancer patients. This study evaluated the present status of the Filipino oncologists’ approach in assessing the quality of life of cancer patients.
Methods
This was a cross-sectional study that utilized a survey questionnaire. Participants included physicians in the care of the cancer patient (consultants & trainees) – medical, surgical, radiation, gynecologic oncologists, and hematologists, who were contacted via email through the database of their respective societies, and personally during scientific meetings / conferences. Descriptive and multivariate analysis were used to analyze the data.
Results
312 oncologists participated. 96% reported that HQRoL assessment was important for clinical work, however 58% perceived HRQoL to be a vague term; 69% agreed that verbal HRQoL assessments were generally enough, and 39% reported that their patients did not accept HRQoL questionnaires. Furthermore, 78% did not know which HRQoL assessment tool to use, and that the questionnaires were too extensive and too lengthy for routine use; 55% reported that they did not feel sufficiently trained to assess HRQoL. About 89.42% reported that they will be more confident if local HRQoL assessment guidelines will be present, and 92.95% agreed to the use of a unified HRQoL assessment tool for Filipino cancer patients.
Conclusions
Filipino oncologists perceived HRQoL patient assessments to be important in clinical practice. However, majority did not know which tool to use and did not feel sufficiently trained to assess HRQoL. The creation of a practice guideline that would facilitate the use of a unified HRQoL assessment tool (containing 5-15 questions) for Filipino cancer patients will be explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract